Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica.

Morrison BF, Aiken WD, Reid ME.

Rev Panam Salud Publica. 2011 Jun;29(6):404-8.

2.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

3.

The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer.

Chon JK, Jacobs SC, Naslund MJ.

J Urol. 2000 Sep;164(3 Pt 1):735-7.

PMID:
10953136
4.
5.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
6.

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.

Bayoumi AM, Brown AD, Garber AM.

J Natl Cancer Inst. 2000 Nov 1;92(21):1731-9.

7.

Monotherapy in advanced prostate cancer: an overview.

Baltogiannis D, Giannakopoulos X, Charalabopoulos K, Sofikitis N.

Exp Oncol. 2004 Sep;26(3):185-91. Review.

PMID:
15494685
8.

[Androgen deprivation for advanced prostate cancer].

Heidenreich A, Pfister D, Ohlmann CH, Engelmann UH.

Urologe A. 2008 Mar;47(3):270-83. doi: 10.1007/s00120-008-1636-2. Review. German.

PMID:
18273599
9.

Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?

Krahn M, Bremner KE, Tomlinson G, Luo J, Ritvo P, Naglie G, Alibhai SM.

BJU Int. 2011 Nov;108(10):1588-96. doi: 10.1111/j.1464-410X.2011.10127.x. Epub 2011 Mar 31.

10.

Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.

Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM.

J Clin Oncol. 2001 Sep 1;19(17):3750-7.

PMID:
11533098
11.

Clinical and economic considerations in the treatment of prostate cancer.

Varenhorst E, Carlsson P, Pedersen K.

Pharmacoeconomics. 1994 Aug;6(2):127-41. Review.

PMID:
10147438
12.

[Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].

Fujikawa K, Awakura Y, Okabe T, Watanabe R, Nishimura S.

Nihon Hinyokika Gakkai Zasshi. 2003 May;94(4):503-11; discussion 511-2. Japanese.

13.

Hormonal therapy for stage D cancer of the prostate.

Gudziak MR, Smith AY.

West J Med. 1994 Apr;160(4):351-9. Review.

14.

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.

Urology. 2003 Jul;62(1):99-104.

PMID:
12837431
15.
17.

Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate.

Hara I, Miyake H, Yamada Y, Takechi Y, Hara S, Gotoh A, Fujisawa M, Okada H, Arakawa S, Soejima T, Sugimura K, Kamidono S.

Int J Urol. 2002 Jun;9(6):322-8; discussion 328.

18.

Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.

Nygård R, Norum J, Due J.

Anticancer Res. 2001 Jan-Feb;21(1B):781-8.

PMID:
11299844
19.

Combined androgen blockade: the gold standard for metastatic prostate cancer.

McLeod DG, Crawford ED, DeAntoni EP.

Eur Urol. 1997;32 Suppl 3:70-7. Review.

PMID:
9267789
20.

The fate of the medically castrated testis: expectation versus reality.

Issa MM, Krishnan A, Bouet R, Young MR, Hood N, Petros JA.

J Urol. 2004 Sep;172(3):1042-4.

PMID:
15311033
Items per page

Supplemental Content

Write to the Help Desk